Rubicon Research IPO GMP History
Rubicon Research IPO has been listed on October 16, 2025 at a listing price of ₹620, against the issue price of ₹485 — a gain of ₹135 (+27.84%). The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Rubicon Research IPO raised ₹1,378 Cr. through its IPO at a price band of ₹461 to ₹485 per share, with a lot size of 30 shares. The IPO was open for subscription from 09 Oct 2025 to 13 Oct 2025.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
GMP trend
Grey market premium sampled three times a day (11 AM, 5 PM, 10 PM). Last updated 3 Sep, 2:08 PM IST.
Day-wise GMP
The last reading of each day, newest first. Arrows compare with the previous day.
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| No GMP history available yet. | |||||
Rubicon Research IPO dates
Key dates from opening to listing. Today is 3 October.
- Open 09 Oct 2025
- Close 13 Oct 2025
- Allotment 14 Oct 2025
- Refund/credit 15 Oct 2025
- Listing 16 Oct 2025
Rubicon Research IPO actual listing price
How the grey market's final call compared with the listing-day open.
| Issue price | ₹485 |
|---|---|
| Listing gain / loss | +₹135 per share |
| Listing date | 16 Oct, 2025 |
| Actual listing price | ₹620 (+27.84%) |
Is Rubicon Research IPO GMP reliable?
Grey market premium for Rubicon Research IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- 01Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- 02Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- 03Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- 04Cross-check before acting: Review the Rubicon Research IPO full review for a fundamentals-based assessment before making any grey market trades.
Rubicon Research IPO Kostak rate explained
Two ways the grey market trades an IPO application before listing.
The Kostak rate for Rubicon Research IPO was not available during the subscription period. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not available for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Rubicon Research IPO
Rubicon Research is a pharmaceutical company focused on developing and manufacturing high-quality generic medicines, with a strong emphasis on complex formulations and drug delivery systems. The company was established with the vision of catering to regulated markets such as the United States and Europe, and over the years, it has built capabilities in research, formulation development, and manufacturing. Rubicon operates through a vertically integrated model, supported by its research and development centres and manufacturing facilities that comply with global regulatory standards.
The company offers a range of pharmaceutical products, including oral solids, injectables, and other specialty formulations, targeting therapeutic segments such as central nervous system (CNS), cardiovascular, and oncology. Rubicon Research is promoted by experienced professionals with deep industry expertise, who have played a key role in shaping its growth strategy and global presence. Its business model is driven by product development partnerships, contract manufacturing, and direct sales in key markets, enabling it to generate revenue through both proprietary products and collaborations with global pharmaceutical companies.
Frequently asked
What is the GMP of Rubicon Research IPO?
The current Grey Market Premium (GMP) of Rubicon Research IPO is not yet started or active in the market.
What is the Kostak Price of Rubicon Research IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Rubicon Research IPO is not available.
What is the Subject to Sauda Price of Rubicon Research IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is not available.
What was the actual listing price of Rubicon Research IPO?
Rubicon Research IPO listed on October 16, 2025 at ₹620, against the issue price of ₹485 — a gain of +27.84%.
How did the GMP of Rubicon Research IPO trend before listing?
The GMP of Rubicon Research IPO was stable in its final days before listing. View the day-wise table above for the complete GMP history.
Explore Rubicon Research IPO further
The grey market is one signal. Read it alongside the demand, the reviews and the filings before you decide.
It has listed — go back to the fundamentals.
Category-wise demand from QIB, NII and retail investors, updated through the day.
What brokers and analysts are saying about this issue, in one place.
Check with your PAN whether shares were credited to your demat account.
The grey market called it. Now check the fundamentals.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Read the grey market alongside the subscription book and the offer document before you apply.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
